Artivion Inc stock hits 52-week high at 44.01 USD

Published 22/08/2025, 15:54
Artivion Inc stock hits 52-week high at 44.01 USD

Artivion Inc stock recently reached a 52-week high, climbing to 44.01 USD. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with multiple indicators suggesting overbought conditions. This milestone underscores a significant upward trend for the company, which has seen its stock price increase by 69.04% over the past year. The impressive gains extend across multiple timeframes, with a notable 52.65% surge in the past six months. Three analysts have recently revised their earnings estimates upward, and while the company wasn’t profitable in the last twelve months, analysts expect positive net income this year. This 52-week high reflects a period of growth and resilience for the company, setting a promising tone for its future prospects in the market. For deeper insights into Artivion’s valuation and 17 additional ProTips, consider exploring the comprehensive research available on InvestingPro.

In other recent news, Artivion Inc. reported second-quarter revenue of $113 million, surpassing consensus expectations and various analyst projections. This strong performance was marked by a 14% to 15.3% year-over-year growth, depending on the analyst report, driven largely by the success of its AMDS stent and stent-graft products. The company’s adjusted EBITDA also exceeded expectations, reaching $24.8 million, which was higher than both Canaccord’s and the consensus estimates. Following these results, Artivion increased its 2025 revenue and EBITDA guidance.

Analyst firms have responded to these developments with various adjustments to Artivion’s stock price targets. Needham raised its price target to $50, while Stifel increased it to $40. Canaccord Genuity also raised its target to $41, maintaining a Buy rating. Conversely, Oppenheimer slightly lowered its price target to $40 but still retained an Outperform rating. These adjustments reflect the analysts’ positive outlook on Artivion’s recent performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.